Follicular lymphoma: time for a re-think?
Follicular lymphoma (FL) is a malignancy of follicle centre B cells that have at least a partially follicular pattern, and is the commonest type of indolent Non-Hodgkin's lymphoma. Except in the subset of patients with localized disease, FL should still be regarded as an incurable malignancy with a relentless relapsing/remitting course. However, the provocative new data covered by this review (including anti-CD20 antibody therapy, BCL-2, radioimmunotherapy, new chemotherapeutic agents and anti-idiotype vaccination), provides much cause for excitement and guarded optimism. Rituximab represents a novel treatment approach for a variety of disease settings, with a proven excellent efficacy and toxicity profile. Long-term data is required to establish whether its use translates into survival benefit. As the clinical activity of rituximab and other new therapeutic approaches becomes established, it will be important to determine how best to integrate these results into the standard care of patients with follicular lymphoma.
Gandhi
Maher K
MK
Department of Haematology, Princess Alexandra Hospital, Brisbane, 4006 QLD, Australia. maherG@qimr.edu.au
Marcus
Robert E
RE
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019254:Genes, bcl-2; D006801:Humans; D016233:Immunotherapy, Active; D016898:Interferon-alpha / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000235:genetics / Q000628:therapy*; D016499:Radioimmunotherapy; D000069283:Rituximab; D033581:Stem Cell Transplantation
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016898:Interferon-alpha; D000069283:Rituximab